SpectraScience’s Luma cervical imaging system was developed to significantly improve the detection of high-grade precancerous cervical abnormalities that have the potential to become invasive cancer.
The Luma system provides a safe and effective method, that when used as an adjunct to colposcopy, has been demonstrated to uncover at least 26% more high-grade precancerous disease than colposcopy alone.
Jim Hitchin, CEO of SpectraScience, said: “We are pleased to have placed our Luma System at the prestigious University of Iowa facility and believe that it is a strong validation of our technology. We are committed to developing and bringing more effective cancer screening technologies to the market with the result of better and earlier diagnosis.”